Provided by Tiger Trade Technology Pte. Ltd.

GH Research PLC

28.33
-0.3500-1.22%
Post-market: 28.330.00000.00%19:30 EDT
Volume:141.75K
Turnover:4.03M
Market Cap:1.94B
PE:-28.74
High:29.22
Open:28.83
Low:28.01
Close:28.68
52wk High:31.44
52wk Low:11.83
Shares:68.56M
Float Shares:29.56M
Volume Ratio:0.60
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9857
EPS(LYR):-0.7900
ROE:-18.79%
ROA:-13.02%
PB:5.40
PE(LYR):-35.86

Loading ...

Definium Therapeutics up 14.5%, Compass Pathways up 21.5%, GH Research up 18.9%, Enveric Biosciences up 6.6%, U.S.‑Listed Shares of Cybin up 15.5%

THOMSON REUTERS
·
Apr 20

BUZZ-Psychedelic drug developers rise after Trump signals regulatory support

Reuters
·
Apr 20

GH Research director Duncan Moore files initial beneficial ownership statement

Reuters
·
Apr 18

GH Research files Form 3 for COO Cameron Aaron Luke beneficial ownership statement

Reuters
·
Apr 03

GH Research files Form 3 for Ireland managing director Halle Magnus Clemensen

Reuters
·
Apr 03

GH Research director Michael Forer files initial beneficial ownership statement

Reuters
·
Apr 03

GH Research files Form 3 showing CEO Velichka Valcheva beneficial ownership

Reuters
·
Apr 03

GH Research files Form 3 for VP Finance Julie Ryan beneficial ownership

Reuters
·
Apr 03

GH Research files Form 3 as director Florian Schonharting reports beneficial ownership

Reuters
·
Apr 02

GH Research announces publication of Phase 2b results for mebufotenin

TIPRANKS
·
Mar 25

GH Research announces JAMA Psychiatry publication of Phase 2b GH001 results in treatment-resistant depression; reports efficacy independent of prior antidepressant failures

Reuters
·
Mar 25

GH Research to join fireside chat at Stifel Virtual CNS Forum

Reuters
·
Mar 16

Analysts Offer Insights on Healthcare Companies: GH Research (GHRS) and Sionna Therapeutics, Inc. (SION)

TIPRANKS
·
Mar 07

Stifel Nicolaus Sticks to Their Buy Rating for GH Research (GHRS)

TIPRANKS
·
Mar 06

Canaccord Genuity Reaffirms Their Buy Rating on GH Research (GHRS)

TIPRANKS
·
Mar 06

GH Research's 2025 Net Loss Widens

MT Newswires Live
·
Mar 05

GH Research plc Publishes Corporate Presentation on Ultra-Rapid, Durable TRD Remission With Inhaled GH001

Reuters
·
Mar 05

GHRS reports FY 2025 cash of USD 280.7 million, up 53.7%

Reuters
·
Mar 05

Press Release: GH Research Reports Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 05

H.C. Wainwright Keeps Their Buy Rating on GH Research (GHRS)

TIPRANKS
·
Mar 02